Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

nd Upcoming Milestones  Esbriet® (pirfenidone):  

  • In advance of its May 26 Analyst Day, InterMune provided a high-level summary of the design of the ASCEND study as follows:  
  • ASCEND will be a placebo-controlled trial of 52 weeks duration with a primary endpoint of change in FVC between baseline and Week 52. The trial will enroll approximately 500 IPF patients with mild-to-moderate impairment in lung function.
  • Relative to the CAPACITY program, the ASCEND study population will be enriched for patients more likely to experience FVC decline and disease progression during the study. 
  • InterMune currently expects to begin enrollment in ASCEND in June 2011. 
  • The study will be primarily enrolled in the United States but will also include sites in Mexico, South America, Australia and New Zealand.
  • InterMune announced on March 3, 2011, that the European Commission (EC) had granted marketing authorization for Esbriet® (pirfenidone).  Esbriet is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.  The approval authorizes marketing of Esbriet in all 27 EU member states.  
  • Additionally, Esbriet has now received marketing authorization in Norway and Iceland.  These countries recognize EU approvals of new medicines.
  • Based on anticipated EU country reimbursement timelines, InterMune currently plans to launch Esbriet as follows: Germany in September of 2011; France, Spain and Italy during the first half of 2012 and the United Kingdom around the middle of 2012.  InterMune also plans to launch Esbriet in all or substantially all of the next five largest pharmaceutical markets in the EU during 2012.  
  • Pre-launch efforts in the areas of Key Opinion Leader development, pricing, reimbursement, market research and staffing continue on schedule with the above t
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. InterMune to Present at Canaccord Adams Conference
    2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
    3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
    4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
    5. InterMune to Release Third Quarter 2008 Financial Results on November 6
    6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
    7. InterMune to Present at Deutsche Bank Biotech Boston Confab
    8. InterMune to Present at J.P. Morgan Healthcare Conference
    9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    11. InterMune Announces Issuance of U.S. Patent for ITMN-191
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/11/2014)... ON , July 11, 2014 /CNW/ - Sunovion ... approved APTIOM TM (eslicarbazepine acetate) for use as ... seizures in patients with epilepsy who are not satisfactorily ... indicated for use in patients under 18 years of ... most common neurological disorders and according to Epilepsy Canada, ...
    (Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
    (Date:7/10/2014)... CA (PRWEB) July 10, 2014 OMICS ... Bioanalytical techniques during 18-20 August, 2014 at Double Tree ... review the recent developments in Analytical & Bioanalytical research ... globe. , Speaking on this occasion, Dr. Srinubabu Gedela, ... Analytica Acta conference is a remarkable one in bringing ...
    (Date:7/10/2014)... 2014  Kainos Capital, a firm specializing in acquiring ... it has acquired the Slim-Fast brand from Unilever. Unilever ... of the transaction were not disclosed. Slim-Fast ... that markets ready-to-drink shakes, powders, bars and snacks to ... and in the United Kingdom ...
    Breaking Biology Technology:Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Kainos Capital Acquires Slim-Fast From Unilever 2
    ... Mich., Sept. 23 Sanford Rose Associates®-Rochester, an ... Rose Associates® network of offices, was recently named ... Sanford Rose Associates®-Rochester was established in January 2009 ... professional searches in the automotive, alternative energy, defense, ...
    ... BEACH, Calif., Sept. 23 Genesis Biopharma, Inc. (OTC Bulletin ... cancer therapies, today announced that it has closed a private ... accredited investors to purchase 933,341 shares of its common stock ... Series A warrants to purchase 466,674 shares at an exercise ...
    ... Association (BMA) Award Winning Medical Authors and Editors -- LONDON, September 23, 2010 ... ... --> ... s = ,; var first_result; // Results are keyed by longUrl, so we need to grab the ...
    Cached Biology Technology:Genesis Biopharma Announces $700K Private Financing 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 2Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 3Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 4Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 5Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 6Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 7Elsevier Congratulates its British Medical Association (BMA) Award Winning Medical Authors and Editors 8
    (Date:7/11/2014)... from the Max Planck Institute for Medical Research in ... understanding photosynthesis, the process by which the Earth first ... and which is therefore crucial for all higher forms ... the first direct visualization of a crucial event in ... specific protein complex, photosystem II, splits water into hydrogen ...
    (Date:7/11/2014)... of kidney injury related to the use of hydroxyethyl ... HES molecules, according to a report in Anesthesia ... Research Society (IARS). , The "total mass of HES ... human renal proximal tubule cells (PTCs), concludes the laboratory ... Hospital Wrzburg, Austria. Other factorssuch as differences in ...
    (Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
    Breaking Biology News(10 mins):A first direct glimpse of photosynthesis in action 2In lab studies, hydroxyethyl starch has direct harmful effects on kidney cells 2
    ... Mich. Ask any political leader if they are ... typically a resounding, "Yes." Evaluating its effectiveness, however, ... and environmental science and policy professor at Michigan State ... evaluate sustainability at a national gathering of scientists Feb. ...
    ... NC How did early humans adapt to different climates and ... the globe? And what does that mean for humans living today? ... and anthropology will present their findings on Sunday February 20th at ... titled "Humans Without Borders: Evolutionary Processes at Work In Humans ...
    ... At this year,s American Association for the Advancement ... to 21, Caltech researchers will present topics ranging from ... in bioengineering. Caltech,s Alice S. Huang, AAAS president, ... highlighting this year,s AAAS theme, "Science Without Borders." ...
    Cached Biology News:It's time to take a unified approach toward measuring sustainability 2Panelists to discuss evolution of human brain size, skin color and diet at AAAS meeting 2Tip sheet: Caltech researchers presenting at AAAS 2Tip sheet: Caltech researchers presenting at AAAS 3
    Automated centrifuge for the processing of microplates and tubes; can be integrated into automated process using inexpensive robotics due to its unique sample handling platform....
    ... is designed for use with HRP conjugated rabbit ... mouse monoclonal coating antibody. • ... prevent non-specific binding between the coating and detection ... may be used to stabilize newly conjugated antibodies, ...
    EZ-Tn5™ Transposase is designed for use with our pMOD™ series of vectors as well as any EZ-Tn5™ transposon system....
    ... PBL's bioassays for interferons are cytopathic effect inhibition ... Sample types include; tissue culture supernatents; serum ... these assays, one unit is defined as the ... the cytopathic effect of viral infection by 50%. ...
    Biology Products: